DeCure for Pituitary hormone deficiency, combined or isolated, 8
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for pituitary hormone deficiency, combined or isolated, 8 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePituitary hormone deficiency, combined or isolated, 8 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pituitary hormone deficiency, combined or isolated, 8 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
roundabout guidance receptor 1 (ROBO1) — ROBO1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5OPE · 2.54 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
In a 1998 study of two consanguineous families with combined pituitary hormone deficiency caused by a PROP1 gene mutation (R120C), five of twelve subjects were affected. Age at diagnosis ranged from 9 months to 8 years, depending on symptom severity. All patients eventually showed severe growth retardation and failure to thrive, mainly from growth hormone deficiency in four cases. Secretion of GH, PRL, TSH, LH, and FSH declined gradually and at different rates per individual. All five entered puberty spontaneously; the two females had menarche and periods before replacement therapy was needed. The same mutation produced variable phenotypes even within these families.
A 2016 review describes subclinical hypopituitarism as an intermediate state between normal pituitary secretion and overt disease. The authors state that clinical manifestations and diagnostic criteria are not well defined, and that the condition is probably underdiagnosed. They note that long-term controlled studies are needed to establish a definition, understand clinical implications, determine optimal diagnostic methods, and clarify indications for substitutive treatment. No concrete numbers on prevalence, progression, or treatment outcomes are given.
A 2010 Russian-language review asserts that traditional replacement hormonal therapy often fails to resolve metabolic disorders in adults with hypopituitarism. It claims that recombinant growth hormone therapy has a positive influence and that replacing all pituitary deficiencies, including GH, allows metabolism to function as close to normal as possible, minimising metabolic consequences. The review provides no patient numbers, response rates, or survival data.
What is still missing: controlled long-term trials that define subclinical hypopituitarism and its natural history; prospective studies linking specific PROP1 mutations to predictable clinical trajectories; and randomised evidence that comprehensive hormone replacement, including GH, reduces morbidity or mortality in adults with hypopituitarism. Patient stratification by age, mutation type, and hormonal decline pattern remains unvalidated.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Clinical Endocrinology & Metabolism · 1998 · 205 citations · open access
Phenotypic Variability in Familial Combined Pituitary Hormone Deficiency Caused by a PROP1 Gene Mutation Resulting in the Substitution of Arg→Cys at Codon 120 (R120C)1
AbstractAs pituitary function depends on the integrity of the hypothalamic-pituitary axis, any defect in the development and organogenesis of this gland may account for a form of combined pituitary hormone deficiency (CPHD). A mutation in a novel, tissue-specific, paired-like homeodomain transcription factor, termed Prophet of Pit-1 (PROP1), has been identified as causing the Ames dwarf (df) mouse phenotype, and thereafter, different PROP1 gene alterations have been found in humans with CPHD. We report on the follow-up of two consanguineous families (n = 12), with five subjects affected with CPHD (three males and two females) caused by the same nucleotide C to T transition, resulting in the substitution of Arg-->Cys in PROP1 at codon 120. Importantly, there is a variability of phenotype, even among patients with the same mutation. The age at diagnosis was dependent on the severity of symptoms, ranging from 9 months to 8 yr. Although in one patient TSH deficiency was the first symptom of the disorder, all patients became symptomatic by exhibiting severe growth retardation and failure to thrive, which was mainly caused by GH deficiency (n = 4). The secretion of the pituitary-derived hormones (GH, PRL, TSH, LH, and FSH) declined gradually with age, following a different pattern in each individual; therefore, the deficiencies developed over a variable period of time. All of the subjects entered puberty spontaneously, and the two females also experienced menarche and periods before a replacement therapy was necessary.
Journal of Steroids & Hormonal Science · 2016 · 2 citations · open access
An Update on Subclinical Hypopituitarism
AbstractSubclinical deficiency of pituitary hormones represents an intermediate situation among normal pituitary secretion and overt hypopituitarism. Clinical hypopituitarism is associated with impaired morbidity and mortality, but there are not many studies on these topics in the subclinical setting. Moreover, clinical manifestations and diagnosis criteria are not well defined, so this entity is probably an underdiagnosed disorder. Long-term controlled studies are needed to establish a correct definition of subclinical hypopituitarism and to know its clinical implications, optimal methods of diagnosis, and indications for substitutive treatment. This review will focus on the evidence related to epidemiology, clinical manifestations, diagnosis, and treatment of subclinical hypopituitarism.
Obesity and metabolism · 2010 · 0 citations · open access
Metabolicheskiy effekt gormona rostapri gipopituitarizme u vzroslykh
AbstractReview coverts the basic metabolic disorders, characteristic for adult patients with hypopituitarism which frequently cannot be solved by means of traditional replacement hormonal therapy. Positive influence of rGH therapy has proved necessity of its application for these patients. Complex replacement of all pituitary deficiencies, including GH, allows an organism to work in the conditions of the hormonal metabolism as much as possible similar to normal, completely leveling or reducing to a minimum of metabolic consequences common for adults with hypopituitarism.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
